Understanding exacerbation risk in BLVR: A logistic regression approach to complication prediction

Area of Science:

• Pulmonary Medicine
• Interventional Pulmonology
• Respiratory Disease Research

Background:

• Chronic Obstructive Pulmonary Disease (COPD) with emphysema causes airflow limitation and exacerbations.
• Bronchoscopic Lung Volume Reduction (BLVR) using endobronchial valves (EBVs) improves lung function but risks complications like pneumonia and exacerbations.
• Predictors for these adverse events after BLVR with EBVs are not fully understood.

Purpose of the Study:

• To identify clinical and inflammatory factors linked to postprocedural exacerbations in patients undergoing BLVR with EBVs.
• To enable individualized risk stratification for patients receiving BLVR therapy.

Main Methods:

• Retrospective analysis of 320 patients with advanced emphysema treated with EBVs (2015-2022).
• Comprehensive preprocedural evaluation including pulmonary function tests, imaging, and COPD Assessment Test.
• Binary logistic regression and multivariable modeling to identify independent predictors of exacerbations within 8 weeks post-procedure.

Main Results:

• 10.9% of patients experienced post-BLVR exacerbations; 6 cases involved pneumonia.
• Independent predictors for exacerbations included diabetes mellitus type II (OR 11.0), elevated C-reactive protein >1 mg/dL (OR 9.35), high WBC count (OR 5.46), frequent prior exacerbations (OR 2.94), and low BMI (OR 0.78).
• The predictive model showed high discriminative ability (AUC = 0.923).

Conclusions:

• Elevated inflammatory markers, diabetes, history of frequent exacerbations, and low BMI are significant independent predictors of early post-BLVR exacerbations.
• Targeted management of these identified risk factors during preprocedural assessment can potentially improve patient safety and outcomes.
• BLVR with EBVs remains a viable option, but careful patient selection and risk factor management are crucial.